Loading Bonafide Research

Global Prostate Cancer Diagnostics and Therapy Market Growth (Status and Outlook) 2024-2030

The global Prostate Cancer Diagnostics and Therapy market, valued at US$ 13,140 million in 2024, is growing as demand rises for specialized diagnostic tools.

The global prostate cancer diagnostics and therapy market is experiencing significant growth due to the rising prevalence of prostate cancer, increasing awareness of early detection, and advancements in diagnostic and therapeutic technologies. Prostate cancer is one of the most commonly diagnosed cancers among men, particularly in aging populations, with lifestyle factors, genetic predisposition, and environmental influences contributing to its increasing incidence. The growing availability of advanced diagnostic tools, including prostate-specific antigen (PSA) tests, digital rectal exams (DRE), magnetic resonance imaging (MRI), and genetic testing, has led to earlier and more accurate detection, improving patient outcomes. The integration of artificial intelligence (AI) and machine learning in diagnostics is further enhancing precision by improving imaging analysis and biomarker identification. Additionally, the introduction of liquid biopsy and next-generation sequencing (NGS) is revolutionizing cancer diagnostics, allowing for non-invasive detection and personalized treatment approaches. Governments and healthcare organizations are actively promoting awareness campaigns and screening programs, driving higher adoption of prostate cancer diagnostics. However, challenges such as the high cost of advanced diagnostic procedures, potential overdiagnosis leading to unnecessary treatments, and disparities in healthcare access in developing regions may hinder market growth. The increasing focus on research and development, along with the approval of innovative diagnostic technologies, is expected to further drive market expansion.

According to Publisher, the global Prostate Cancer Diagnostics and Therapy market size was valued at US$ 13140 million in 2024. With growing demand in downstream market, the Prostate Cancer Diagnostics and Therapy is forecast to a readjusted size of US$ 17460 million by 2030 with a CAGR of 4.1% during review period. The therapeutic landscape of prostate cancer is evolving with the introduction of novel treatment modalities, targeted therapies, and precision medicine approaches. Traditional treatments such as surgery, radiation therapy, and androgen deprivation therapy (ADT) remain widely used, but the emergence of immunotherapies, hormone-based treatments, and radiopharmaceuticals is reshaping the market. Targeted therapies, including androgen receptor inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors, have demonstrated improved efficacy in patients with advanced or metastatic prostate cancer. The growing adoption of immunotherapy, particularly immune checkpoint inhibitors, is offering new hope for patients with resistant or recurrent cancer. Radiopharmaceuticals, such as lutetium-based therapies, are gaining traction for their ability to deliver targeted radiation to cancer cells while minimizing damage to healthy tissues. Additionally, advances in robotic-assisted surgery and minimally invasive treatment techniques are improving surgical outcomes and reducing recovery times. Personalized medicine approaches, guided by genetic testing and biomarker analysis, are allowing for more tailored treatment plans that enhance efficacy and minimize side effects. Despite these advancements, challenges such as treatment resistance, high costs of targeted therapies, and regulatory hurdles in drug approvals remain key concerns for market stakeholders. Increasing investments in clinical trials, collaborations between pharmaceutical companies and research institutions, and ongoing technological innovations are expected to accelerate the development of more effective and accessible prostate cancer therapies.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample
The market is segmented based on diagnostic techniques, including prostate-specific antigen (PSA) tests, digital rectal exams (DRE), imaging techniques, biopsy procedures, and genetic testing. PSA tests remain the most widely used screening method, offering a simple and cost-effective way to detect elevated prostate-specific antigen levels, which may indicate cancer or other prostate conditions. However, the limitations of PSA tests, such as false positives and overdiagnosis, have led to the increasing adoption of advanced imaging technologies, including multiparametric MRI (mpMRI) and positron emission tomography-computed tomography (PET-CT). These imaging modalities provide more accurate tumor detection and staging, reducing the need for unnecessary biopsies. Biopsy procedures, including transrectal ultrasound (TRUS)-guided and transperineal biopsies, remain the gold standard for confirming prostate cancer diagnosis. The integration of AI in biopsy analysis is improving diagnostic accuracy and efficiency. Genetic testing and liquid biopsy are emerging as promising diagnostic tools, allowing for the detection of genetic mutations and circulating tumor DNA (ctDNA) in the blood, which can aid in early detection and treatment selection. The growing preference for non-invasive and highly specific diagnostic techniques is driving continuous innovation in the market.

The therapeutic segment of the market is categorized based on treatment types, including hormone therapy, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and surgical interventions. Hormone therapy, also known as androgen deprivation therapy (ADT), is widely used to suppress the production of testosterone, which fuels prostate cancer growth. While effective in slowing disease progression, long-term use of ADT can lead to resistance, necessitating the development of newer hormone-based treatments, such as androgen receptor inhibitors. Chemotherapy, including docetaxel and cabazitaxel, remains an important option for advanced-stage prostate cancer, particularly for patients who no longer respond to hormone therapy. Radiation therapy, including external beam radiation therapy (EBRT) and brachytherapy, continues to play a crucial role in localized prostate cancer treatment. Targeted therapies, such as PARP inhibitors (olaparib, rucaparib) and radiopharmaceuticals, are gaining prominence due to their ability to selectively attack cancer cells while minimizing side effects. Immunotherapy, particularly immune checkpoint inhibitors, is an emerging area of interest, although its effectiveness in prostate cancer remains an area of ongoing research. Robotic-assisted prostatectomy and minimally invasive surgical techniques are improving surgical outcomes and reducing recovery times. The increasing focus on combination therapies, clinical trials evaluating novel drug candidates, and precision medicine approaches is expected to further drive advancements in prostate cancer treatment, shaping the future of the market.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari

Table of Contents

  • 1 Scope of the Report
  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered
  • 1.8 Market Estimation Caveats
  • 2 Executive Summary
  • 2.1 World Market Overview
  • 2.1.1 Global Prostate Cancer Diagnostics and Therapy Market Size 2019-2030
  • 2.1.2 Prostate Cancer Diagnostics and Therapy Market Size CAGR by Region 2019 VS 2023 VS 2030
  • 2.2 Prostate Cancer Diagnostics and Therapy Segment by Type
  • 2.2.1 Androgen Receptor-Directed Therapy
  • 2.2.2 Taxane-Based Chemotherapy
  • 2.3 Prostate Cancer Diagnostics and Therapy Market Size by Type
  • 2.3.1 Prostate Cancer Diagnostics and Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
  • 2.3.2 Global Prostate Cancer Diagnostics and Therapy Market Size Market Share by Type (2019-2024)
  • 2.4 Prostate Cancer Diagnostics and Therapy Segment by Application
  • 2.4.1 Hospitals
  • 2.4.2 Clinics
  • 2.4.3 Others
  • 2.5 Prostate Cancer Diagnostics and Therapy Market Size by Application
  • 2.5.1 Prostate Cancer Diagnostics and Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
  • 2.5.2 Global Prostate Cancer Diagnostics and Therapy Market Size Market Share by Application (2019-2024)
  • 3 Prostate Cancer Diagnostics and Therapy Market Size by Player
  • 3.1 Prostate Cancer Diagnostics and Therapy Market Size Market Share by Players
  • 3.1.1 Global Prostate Cancer Diagnostics and Therapy Revenue by Players (2019-2024)
  • 3.1.2 Global Prostate Cancer Diagnostics and Therapy Revenue Market Share by Players (2019-2024)
  • 3.2 Global Prostate Cancer Diagnostics and Therapy Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
  • 3.3.1 Competition Landscape Analysis
  • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion
  • 4 Prostate Cancer Diagnostics and Therapy by Regions
  • 4.1 Prostate Cancer Diagnostics and Therapy Market Size by Regions (2019-2024)
  • 4.2 Americas Prostate Cancer Diagnostics and Therapy Market Size Growth (2019-2024)
  • 4.3 APAC Prostate Cancer Diagnostics and Therapy Market Size Growth (2019-2024)
  • 4.4 Europe Prostate Cancer Diagnostics and Therapy Market Size Growth (2019-2024)
  • 4.5 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size Growth (2019-2024)
  • 5 Americas
  • 5.1 Americas Prostate Cancer Diagnostics and Therapy Market Size by Country (2019-2024)
  • 5.2 Americas Prostate Cancer Diagnostics and Therapy Market Size by Type (2019-2024)
  • 5.3 Americas Prostate Cancer Diagnostics and Therapy Market Size by Application (2019-2024)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil
  • 6 APAC
  • 6.1 APAC Prostate Cancer Diagnostics and Therapy Market Size by Region (2019-2024)
  • 6.2 APAC Prostate Cancer Diagnostics and Therapy Market Size by Type (2019-2024)
  • 6.3 APAC Prostate Cancer Diagnostics and Therapy Market Size by Application (2019-2024)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 7 Europe
  • 7.1 Europe Prostate Cancer Diagnostics and Therapy by Country (2019-2024)
  • 7.2 Europe Prostate Cancer Diagnostics and Therapy Market Size by Type (2019-2024)
  • 7.3 Europe Prostate Cancer Diagnostics and Therapy Market Size by Application (2019-2024)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia
  • 8 Middle East & Africa
  • 8.1 Middle East & Africa Prostate Cancer Diagnostics and Therapy by Region (2019-2024)
  • 8.2 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Type (2019-2024)
  • 8.3 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Application (2019-2024)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends
  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends
  • 10 Global Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.1 Global Prostate Cancer Diagnostics and Therapy Forecast by Regions (2025-2030)
  • 10.1.1 Global Prostate Cancer Diagnostics and Therapy Forecast by Regions (2025-2030)
  • 10.1.2 Americas Prostate Cancer Diagnostics and Therapy Forecast
  • 10.1.3 APAC Prostate Cancer Diagnostics and Therapy Forecast
  • 10.1.4 Europe Prostate Cancer Diagnostics and Therapy Forecast
  • 10.1.5 Middle East & Africa Prostate Cancer Diagnostics and Therapy Forecast
  • 10.2 Americas Prostate Cancer Diagnostics and Therapy Forecast by Country (2025-2030)
  • 10.2.1 United States Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.2.2 Canada Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.2.3 Mexico Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.2.4 Brazil Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.3 APAC Prostate Cancer Diagnostics and Therapy Forecast by Region (2025-2030)
  • 10.3.1 China Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.3.2 Japan Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.3.3 Korea Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.3.4 Southeast Asia Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.3.5 India Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.3.6 Australia Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.4 Europe Prostate Cancer Diagnostics and Therapy Forecast by Country (2025-2030)
  • 10.4.1 Germany Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.4.2 France Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.4.3 UK Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.4.4 Italy Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.4.5 Russia Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.5 Middle East & Africa Prostate Cancer Diagnostics and Therapy Forecast by Region (2025-2030)
  • 10.5.1 Egypt Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.5.2 South Africa Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.5.3 Israel Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.5.4 Turkey Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.5.5 GCC Countries Prostate Cancer Diagnostics and Therapy Market Forecast
  • 10.6 Global Prostate Cancer Diagnostics and Therapy Forecast by Type (2025-2030)
  • 10.7 Global Prostate Cancer Diagnostics and Therapy Forecast by Application (2025-2030)
  • 11 Key Players Analysis
  • 11.1 Ipsen SA
  • 11.1.1 Ipsen SA Company Information
  • 11.1.2 Ipsen SA Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.1.3 Ipsen SA Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.1.4 Ipsen SA Main Business Overview
  • 11.1.5 Ipsen SA Latest Developments
  • 11.2 Pfizer Inc.
  • 11.2.1 Pfizer Inc. Company Information
  • 11.2.2 Pfizer Inc. Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.2.3 Pfizer Inc. Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.2.4 Pfizer Inc. Main Business Overview
  • 11.2.5 Pfizer Inc. Latest Developments
  • 11.3 Johnson & Johnson Services Inc.
  • 11.3.1 Johnson & Johnson Services Inc. Company Information
  • 11.3.2 Johnson & Johnson Services Inc. Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.3.3 Johnson & Johnson Services Inc. Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.3.4 Johnson & Johnson Services Inc. Main Business Overview
  • 11.3.5 Johnson & Johnson Services Inc. Latest Developments
  • 11.4 Bayer AG
  • 11.4.1 Bayer AG Company Information
  • 11.4.2 Bayer AG Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.4.3 Bayer AG Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.4.4 Bayer AG Main Business Overview
  • 11.4.5 Bayer AG Latest Developments
  • 11.5 Abbvie Inc.
  • 11.5.1 Abbvie Inc. Company Information
  • 11.5.2 Abbvie Inc. Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.5.3 Abbvie Inc. Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.5.4 Abbvie Inc. Main Business Overview
  • 11.5.5 Abbvie Inc. Latest Developments
  • 11.6 Merck & Co. Inc.
  • 11.6.1 Merck & Co. Inc. Company Information
  • 11.6.2 Merck & Co. Inc. Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.6.3 Merck & Co. Inc. Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.6.4 Merck & Co. Inc. Main Business Overview
  • 11.6.5 Merck & Co. Inc. Latest Developments
  • 11.7 AstraZeneca PLC
  • 11.7.1 AstraZeneca PLC Company Information
  • 11.7.2 AstraZeneca PLC Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.7.3 AstraZeneca PLC Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.7.4 AstraZeneca PLC Main Business Overview
  • 11.7.5 AstraZeneca PLC Latest Developments
  • 11.8 Thermo Fisher Scientific
  • 11.8.1 Thermo Fisher Scientific Company Information
  • 11.8.2 Thermo Fisher Scientific Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.8.3 Thermo Fisher Scientific Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.8.4 Thermo Fisher Scientific Main Business Overview
  • 11.8.5 Thermo Fisher Scientific Latest Developments
  • 11.9 Dendreon Pharmaceuticals LLC
  • 11.9.1 Dendreon Pharmaceuticals LLC Company Information
  • 11.9.2 Dendreon Pharmaceuticals LLC Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.9.3 Dendreon Pharmaceuticals LLC Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.9.4 Dendreon Pharmaceuticals LLC Main Business Overview
  • 11.9.5 Dendreon Pharmaceuticals LLC Latest Developments
  • 11.10 F. Hoffmann-La Roche Ltd
  • 11.10.1 F. Hoffmann-La Roche Ltd Company Information
  • 11.10.2 F. Hoffmann-La Roche Ltd Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.10.3 F. Hoffmann-La Roche Ltd Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.10.4 F. Hoffmann-La Roche Ltd Main Business Overview
  • 11.10.5 F. Hoffmann-La Roche Ltd Latest Developments
  • 11.11 Hologic Inc.
  • 11.11.1 Hologic Inc. Company Information
  • 11.11.2 Hologic Inc. Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.11.3 Hologic Inc. Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.11.4 Hologic Inc. Main Business Overview
  • 11.11.5 Hologic Inc. Latest Developments
  • 11.12 Astellas Pharma Inc.
  • 11.12.1 Astellas Pharma Inc. Company Information
  • 11.12.2 Astellas Pharma Inc. Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.12.3 Astellas Pharma Inc. Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.12.4 Astellas Pharma Inc. Main Business Overview
  • 11.12.5 Astellas Pharma Inc. Latest Developments
  • 11.13 Koninklijke Philips NV
  • 11.13.1 Koninklijke Philips NV Company Information
  • 11.13.2 Koninklijke Philips NV Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.13.3 Koninklijke Philips NV Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.13.4 Koninklijke Philips NV Main Business Overview
  • 11.13.5 Koninklijke Philips NV Latest Developments
  • 11.14 Sanofi-Aventis
  • 11.14.1 Sanofi-Aventis Company Information
  • 11.14.2 Sanofi-Aventis Prostate Cancer Diagnostics and Therapy Product Offered
  • 11.14.3 Sanofi-Aventis Prostate Cancer Diagnostics and Therapy Revenue, Gross Margin and Market Share (2019-2024)
  • 11.14.4 Sanofi-Aventis Main Business Overview
  • 11.14.5 Sanofi-Aventis Latest Developments
  • 12 Research Findings and Conclusion


Table 1. Prostate Cancer Diagnostics and Therapy Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Androgen Receptor-Directed Therapy
Table 3. Major Players of Taxane-Based Chemotherapy
Table 4. Prostate Cancer Diagnostics and Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 5. Global Prostate Cancer Diagnostics and Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 6. Global Prostate Cancer Diagnostics and Therapy Market Size Market Share by Type (2019-2024)
Table 7. Prostate Cancer Diagnostics and Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Prostate Cancer Diagnostics and Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 9. Global Prostate Cancer Diagnostics and Therapy Market Size Market Share by Application (2019-2024)
Table 10. Global Prostate Cancer Diagnostics and Therapy Revenue by Players (2019-2024) & ($ Millions)
Table 11. Global Prostate Cancer Diagnostics and Therapy Revenue Market Share by Player (2019-2024)
Table 12. Prostate Cancer Diagnostics and Therapy Key Players Head office and Products Offered
Table 13. Prostate Cancer Diagnostics and Therapy Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Prostate Cancer Diagnostics and Therapy Market Size by Regions 2019-2024 & ($ Millions)
Table 17. Global Prostate Cancer Diagnostics and Therapy Market Size Market Share by Regions (2019-2024)
Table 18. Global Prostate Cancer Diagnostics and Therapy Revenue by Country/Region (2019-2024) & ($ millions)
Table 19. Global Prostate Cancer Diagnostics and Therapy Revenue Market Share by Country/Region (2019-2024)
Table 20. Americas Prostate Cancer Diagnostics and Therapy Market Size by Country (2019-2024) & ($ Millions)
Table 21. Americas Prostate Cancer Diagnostics and Therapy Market Size Market Share by Country (2019-2024)
Table 22. Americas Prostate Cancer Diagnostics and Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 23. Americas Prostate Cancer Diagnostics and Therapy Market Size Market Share by Type (2019-2024)
Table 24. Americas Prostate Cancer Diagnostics and Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 25. Americas Prostate Cancer Diagnostics and Therapy Market Size Market Share by Application (2019-2024)
Table 26. APAC Prostate Cancer Diagnostics and Therapy Market Size by Region (2019-2024) & ($ Millions)
Table 27. APAC Prostate Cancer Diagnostics and Therapy Market Size Market Share by Region (2019-2024)
Table 28. APAC Prostate Cancer Diagnostics and Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 29. APAC Prostate Cancer Diagnostics and Therapy Market Size Market Share by Type (2019-2024)
Table 30. APAC Prostate Cancer Diagnostics and Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 31. APAC Prostate Cancer Diagnostics and Therapy Market Size Market Share by Application (2019-2024)
Table 32. Europe Prostate Cancer Diagnostics and Therapy Market Size by Country (2019-2024) & ($ Millions)
Table 33. Europe Prostate Cancer Diagnostics and Therapy Market Size Market Share by Country (2019-2024)
Table 34. Europe Prostate Cancer Diagnostics and Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 35. Europe Prostate Cancer Diagnostics and Therapy Market Size Market Share by Type (2019-2024)
Table 36. Europe Prostate Cancer Diagnostics and Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 37. Europe Prostate Cancer Diagnostics and Therapy Market Size Market Share by Application (2019-2024)
Table 38. Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Region (2019-2024) & ($ Millions)
Table 39. Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size Market Share by Region (2019-2024)
Table 40. Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size Market Share by Type (2019-2024)
Table 42. Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size Market Share by Application (2019-2024)
Table 44. Key Market Drivers & Growth Opportunities of Prostate Cancer Diagnostics and Therapy
Table 45. Key Market Challenges & Risks of Prostate Cancer Diagnostics and Therapy
Table 46. Key Industry Trends of Prostate Cancer Diagnostics and Therapy
Table 47. Global Prostate Cancer Diagnostics and Therapy Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 48. Global Prostate Cancer Diagnostics and Therapy Market Size Market Share Forecast by Regions (2025-2030)
Table 49. Global Prostate Cancer Diagnostics and Therapy Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 50. Global Prostate Cancer Diagnostics and Therapy Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 51. Ipsen SA Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 52. Ipsen SA Prostate Cancer Diagnostics and Therapy Product Offered
Table 53. Ipsen SA Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Ipsen SA Main Business
Table 55. Ipsen SA Latest Developments
Table 56. Pfizer Inc. Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 57. Pfizer Inc. Prostate Cancer Diagnostics and Therapy Product Offered
Table 58. Pfizer Inc. Main Business
Table 59. Pfizer Inc. Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 60. Pfizer Inc. Latest Developments
Table 61. Johnson & Johnson Services Inc. Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 62. Johnson & Johnson Services Inc. Prostate Cancer Diagnostics and Therapy Product Offered
Table 63. Johnson & Johnson Services Inc. Main Business
Table 64. Johnson & Johnson Services Inc. Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 65. Johnson & Johnson Services Inc. Latest Developments
Table 66. Bayer AG Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 67. Bayer AG Prostate Cancer Diagnostics and Therapy Product Offered
Table 68. Bayer AG Main Business
Table 69. Bayer AG Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 70. Bayer AG Latest Developments
Table 71. Abbvie Inc. Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 72. Abbvie Inc. Prostate Cancer Diagnostics and Therapy Product Offered
Table 73. Abbvie Inc. Main Business
Table 74. Abbvie Inc. Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 75. Abbvie Inc. Latest Developments
Table 76. Merck & Co. Inc. Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 77. Merck & Co. Inc. Prostate Cancer Diagnostics and Therapy Product Offered
Table 78. Merck & Co. Inc. Main Business
Table 79. Merck & Co. Inc. Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 80. Merck & Co. Inc. Latest Developments
Table 81. AstraZeneca PLC Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 82. AstraZeneca PLC Prostate Cancer Diagnostics and Therapy Product Offered
Table 83. AstraZeneca PLC Main Business
Table 84. AstraZeneca PLC Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 85. AstraZeneca PLC Latest Developments
Table 86. Thermo Fisher Scientific Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 87. Thermo Fisher Scientific Prostate Cancer Diagnostics and Therapy Product Offered
Table 88. Thermo Fisher Scientific Main Business
Table 89. Thermo Fisher Scientific Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 90. Thermo Fisher Scientific Latest Developments
Table 91. Dendreon Pharmaceuticals LLC Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 92. Dendreon Pharmaceuticals LLC Prostate Cancer Diagnostics and Therapy Product Offered
Table 93. Dendreon Pharmaceuticals LLC Main Business
Table 94. Dendreon Pharmaceuticals LLC Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 95. Dendreon Pharmaceuticals LLC Latest Developments
Table 96. F. Hoffmann-La Roche Ltd Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 97. F. Hoffmann-La Roche Ltd Prostate Cancer Diagnostics and Therapy Product Offered
Table 98. F. Hoffmann-La Roche Ltd Main Business
Table 99. F. Hoffmann-La Roche Ltd Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 100. F. Hoffmann-La Roche Ltd Latest Developments
Table 101. Hologic Inc. Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 102. Hologic Inc. Prostate Cancer Diagnostics and Therapy Product Offered
Table 103. Hologic Inc. Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 104. Hologic Inc. Main Business
Table 105. Hologic Inc. Latest Developments
Table 106. Astellas Pharma Inc. Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 107. Astellas Pharma Inc. Prostate Cancer Diagnostics and Therapy Product Offered
Table 108. Astellas Pharma Inc. Main Business
Table 109. Astellas Pharma Inc. Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 110. Astellas Pharma Inc. Latest Developments
Table 111. Koninklijke Philips NV Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 112. Koninklijke Philips NV Prostate Cancer Diagnostics and Therapy Product Offered
Table 113. Koninklijke Philips NV Main Business
Table 114. Koninklijke Philips NV Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 115. Koninklijke Philips NV Latest Developments
Table 116. Sanofi-Aventis Details, Company Type, Prostate Cancer Diagnostics and Therapy Area Served and Its Competitors
Table 117. Sanofi-Aventis Prostate Cancer Diagnostics and Therapy Product Offered
Table 118. Sanofi-Aventis Main Business
Table 119. Sanofi-Aventis Prostate Cancer Diagnostics and Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 120. Sanofi-Aventis Latest Developments
List of


Figure 1. Prostate Cancer Diagnostics and Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Prostate Cancer Diagnostics and Therapy Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Prostate Cancer Diagnostics and Therapy Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Prostate Cancer Diagnostics and Therapy Sales Market Share by Country/Region (2023)
Figure 8. Prostate Cancer Diagnostics and Therapy Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Prostate Cancer Diagnostics and Therapy Market Size Market Share by Type in 2023
Figure 10. Prostate Cancer Diagnostics and Therapy in Hospitals
Figure 11. Global Prostate Cancer Diagnostics and Therapy Market: Hospitals (2019-2024) & ($ Millions)
Figure 12. Prostate Cancer Diagnostics and Therapy in Clinics
Figure 13. Global Prostate Cancer Diagnostics and Therapy Market: Clinics (2019-2024) & ($ Millions)
Figure 14. Prostate Cancer Diagnostics and Therapy in Others
Figure 15. Global Prostate Cancer Diagnostics and Therapy Market: Others (2019-2024) & ($ Millions)
Figure 16. Global Prostate Cancer Diagnostics and Therapy Market Size Market Share by Application in 2023
Figure 17. Global Prostate Cancer Diagnostics and Therapy Revenue Market Share by Player in 2023
Figure 18. Global Prostate Cancer Diagnostics and Therapy Market Size Market Share by Regions (2019-2024)
Figure 19. Americas Prostate Cancer Diagnostics and Therapy Market Size 2019-2024 ($ Millions)
Figure 20. APAC Prostate Cancer Diagnostics and Therapy Market Size 2019-2024 ($ Millions)
Figure 21. Europe Prostate Cancer Diagnostics and Therapy Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size 2019-2024 ($ Millions)
Figure 23. Americas Prostate Cancer Diagnostics and Therapy Value Market Share by Country in 2023
Figure 24. United States Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC Prostate Cancer Diagnostics and Therapy Market Size Market Share by Region in 2023
Figure 29. APAC Prostate Cancer Diagnostics and Therapy Market Size Market Share by Type in 2023
Figure 30. APAC Prostate Cancer Diagnostics and Therapy Market Size Market Share by Application in 2023
Figure 31. China Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 35. India Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe Prostate Cancer Diagnostics and Therapy Market Size Market Share by Country in 2023
Figure 38. Europe Prostate Cancer Diagnostics and Therapy Market Size Market Share by Type (2019-2024)
Figure 39. Europe Prostate Cancer Diagnostics and Therapy Market Size Market Share by Application (2019-2024)
Figure 40. Germany Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 41. France Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country Prostate Cancer Diagnostics and Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 54. APAC Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 55. Europe Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 57. United States Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 58. Canada Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 59. Mexico Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 60. Brazil Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 61. China Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 62. Japan Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 63. Korea Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 65. India Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 66. Australia Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 67. Germany Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 68. France Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 69. UK Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 70. Italy Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 71. Russia Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 72. Spain Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 73. Egypt Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 74. South Africa Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 75. Israel Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 76. Turkey Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries Prostate Cancer Diagnostics and Therapy Market Size 2025-2030 ($ Millions)
Figure 78. Global Prostate Cancer Diagnostics and Therapy Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global Prostate Cancer Diagnostics and Therapy Market Size Market Share Forecast by Application (2025-2030)
Logo

Global Prostate Cancer Diagnostics and Therapy Market Growth (Status and Outlook) 2024-2030

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Claude Summarize

Contact usWe are friendly and approachable, give us a call.